タウリンは,Nrf2とNF-κB経路の二重調節を通じてジェンタミシン誘発の神経毒性から保護します
Amira E Farage1, Medhat Taha2, Basma Adel Khattab3
1Department of Anatomy and Embryology, Faculty of Medicine, Kafrelsheikh University, Kafr Elsheikh 33511, Egypt.
Tissue & cell
|February 17, 2026
まとめ
タウリンは,ネズミのゲンタミシン誘発性神経毒性に対して効果的に保護しました. 行動を改善し,脳損傷,酸化ストレス,炎症,アポトーシスを軽減し,神経保護的可能性を強調しました.
科学分野:
- 神経科学は神経科学である.
- 薬理学 薬理学とは
- 毒理学 毒理学 毒理学
背景:
- 抗生物質であるジェンタミシン (GM) は,神経毒性を引き起こし,認知および行動的欠陥につながる可能性があります.
- アミノ酸であるタウリンには,既知の神経保護性があります.
- ジェンタミシン誘発の神経毒性を軽減するタウリンの役割を理解することは,治療戦略の開発に不可欠です.
研究 の 目的:
- ゲンタミシン誘発性神経毒性に対するタウリンの神経保護効果をSprague Dawleyラットで調査する.
- ジェンタミシン暴露後の行動,海馬の構造,酸化ストレス,神経炎症,アポトーシスに対するタウリンの影響を評価する.
主な方法:
- 32匹のラットはコントロール,タウリン,ジェンタミシン (GM),タウリン+GMのグループに分けられました.
- 行動テスト (オープンフィールド,Y-迷宮) は,運動運動,不安,記憶を評価した.
- ヒポキャンパスの組織は,ヒト病理学,免疫ヒスト化学,ELISA,RT-qPCRで分析されました.
主要な成果:
- GMの投与は,不安,海馬の変性,酸化ストレス (MDAの増加,SOD/CATの減少),神経炎症 (NF-B,TNF-α,IL-1β,IL-6の上昇),およびアポトーシス (カスパース-3の増加,バックス;Bcl-2の減少) を誘発した.
- タウリンとの併用治療は,これらの遺伝子組み換えによる影響を逆転させ,行動を改善し,神経細胞の完全性を保ちました.
- タウリンは抗酸化防御 (Nrf2/HO-1経路) を回復させ,炎症を抑制し,アポプトシスマーカーを調節した.
結論:
- タウリンは,ネズミのゲンタミシンの毒性に対する重要な神経保護を示しています.
- そのメカニズムは,抗酸化能力の強化,神経炎症の減少,神経細胞のアポトーシスの抑制を含む.
- タウリンは,ジェンタミシン誘発の神経毒性に対する治療薬として有望である.
関連する概念動画
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
16
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
16
NF-κB-dependent Signaling Pathway
10.1K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
10.1K
Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
Enzyme-linked Receptors
87.0K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
87.0K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
962
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
962


